Loading...

Caladrius Biosciences, Inc.

CLBS•NASDAQ
Healthcare
Biotechnology
$0.43
$-0.09(-16.75%)

Caladrius Biosciences, Inc. (CLBS) Stock Overview

Explore Caladrius Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap3.4M
P/E Ratio-0.24
EPS (TTM)$-0.39
ROE-0.44%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.20

CLBS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Caladrius Biosciences, Inc. (CLBS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.20.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.24 and a market capitalization of 3.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for CLBSStats details for CLBS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CLBSAnalyst Recommendations details for CLBS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

CEO

David Mazzo

Employees

27

Headquarters

110 Allen Rd, Basking Ridge, NJ

Founded

1995

Frequently Asked Questions

;